These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 16809614

  • 1. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.
    Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J.
    Blood; 2006 Oct 15; 108(8):2811-3. PubMed ID: 16809614
    [Abstract] [Full Text] [Related]

  • 2. Myelodysplastic syndrome with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment for chronic myeloid leukemia.
    Karimata K, Masuko M, Ushiki T, Kozakai T, Shibasaki Y, Yano T, Abe T, Moriyama M, Toba K, Furukawa T, Aizawa Y.
    Intern Med; 2011 Oct 15; 50(5):481-5. PubMed ID: 21372464
    [Abstract] [Full Text] [Related]

  • 3. Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases.
    Herens C, Baron F, Croisiau C, Tassin F, Bours V.
    Cancer Genet Cytogenet; 2003 Nov 15; 147(1):78-80. PubMed ID: 14580776
    [Abstract] [Full Text] [Related]

  • 4. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
    Pawarode A, Sait SN, Nganga A, Coignet LJ, Barcos M, Baer MR.
    Leuk Res; 2007 Nov 15; 31(11):1589-92. PubMed ID: 17391756
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
    Deininger MW, Cortes J, Paquette R, Park B, Hochhaus A, Baccarani M, Stone R, Fischer T, Kantarjian H, Niederwieser D, Gambacorti-Passerini C, So C, Gathmann I, Goldman JM, Smith D, Druker BJ, Guilhot F.
    Cancer; 2007 Oct 01; 110(7):1509-19. PubMed ID: 17702093
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Reciprocal relationship between a Ph-negative clone with trisomy 8 associated with severe myelodysplasia and a Ph-positive clone following imatinib treatment in a patient with accelerated-phase chronic myelogenous leukemia (CML).
    Patchenko P, Klepfish A, Trakhtenbrot L, Rothman R, Rachmilewitz EA.
    Am J Hematol; 2004 Dec 01; 77(4):420. PubMed ID: 15558793
    [No Abstract] [Full Text] [Related]

  • 11. Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate.
    Espinet B, Oliveira AC, Boqué C, Domingo A, Alonso E, Solé F.
    Haematologica; 2005 Apr 01; 90(4):556-8. PubMed ID: 15820956
    [Abstract] [Full Text] [Related]

  • 12. The first case of Philadelphia chromosome-negative acute promyelocytic leukemia following imatinib for chronic myelogenous leukemia.
    Wakim JJ, Tirado CA, Dowell J, Chen W.
    Cancer Genet; 2012 Mar 01; 205(3):124-7. PubMed ID: 22469511
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q, Chen SS, Jiang B, Jiang H, Lu Y, Qiu JY, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 01; 26(1):23-6. PubMed ID: 15946504
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors.
    Lin Y, Bruyère H, Horsman DE, Pantzar T, Barnett MJ, Hogge DE, Nevill TJ, Nantel SH, Sutherland HJ, Toze CL, Shepherd JD, Lavoie JC, Song KW, Smith CA, Forrest DL.
    Cancer Genet Cytogenet; 2006 Oct 01; 170(1):16-23. PubMed ID: 16965950
    [Abstract] [Full Text] [Related]

  • 18. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB, Talpaz M, Garcia-Manero G, Faderl S, Letvak L, Salvado A, Kantarjian H.
    Cancer; 2003 Jun 01; 97(11):2760-6. PubMed ID: 12767088
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP, Croom KF, Goa KL.
    BioDrugs; 2004 Jun 01; 18(3):207-10. PubMed ID: 15161340
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.